Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle

• Status: Completed
• Trial end date: 2018-12-03
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this pharmacodynamic and pharmacokinetic study is to identify a dose of TV-46046 (within the range 80 to 300 mg) that is both safe and consistent with contraceptive effect when injected every 6 months.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Teva Branded Pharmaceutical Products, R&D Inc.
• Collaborator: FHI 360
• Treatments: Medroxyprogesterone; Medroxyprogesterone Acetate

Criteria

Inclusion Criteria:

• has regular menstrual cycle (24 to 35 days)

• is at low risk of pregnancy (ie, sterilized, in exclusively same-sex partnership, in monogamous relationship with vasectomized partner, or using non-hormonal IUD)

• is in good general health as determined by a medical history and physical examination

• is not pregnant and does not have desire to become pregnant in the subsequent 36 months

• has had a normal mammogram within the last year (for Part 1 only)

• additional criteria apply, please contact the investigator for more information

Exclusion Criteria:

• has hypertension:

• systolic blood pressure (BP) ≥160 mm Hg or diastolic BP ≥100 mm Hg

• vascular disease

• has current or history of ischemic heart disease

• has history of stroke

• has history of thromboembolic event

• has systemic lupus erythematosus

• positive (or unknown) antiphospholipid antibodies

• severe thrombocytopenia

• has rheumatoid arthritis on immunosuppressive therapy

• has migraine with aura

• has unexplained vaginal bleeding

• has diabetes

• has strong family history of breast cancer (defined as one or more first degree relatives, breast cancer occurring before menopause in three or more family members, regardless of degree of relationship, and any male family member with breast cancer), or current or history of breast cancer, or undiagnosed mass detected by breast exam

• has current or history of cervical cancer

• has severe cirrhosis (decompensated) or liver tumors

• has known significant renal disease

• used Depo-Provera Contraceptive Injection or Depo-subcutaneous Provera 104 (DMPA) products in the past 12 months

• used any of the following medications within 1 month prior to enrollment:

• any investigational drug

• prohibited drugs per protocol

• oral contraceptives, contraceptive ring or patch

• levonorgestrel intrauterine system (LNG IUS) or contraceptive implant

• used a combined injectable contraceptive in the past 6 months

• less than 3 months since the end of last pregnancy

• currently lactating

• is using or plans to use prohibited drugs per protocol in the next 18 months

• has known sensitivity to MPA or inactive ingredients

• has a plan to move to another location in the next 24 months

• in the opinion of the investigator, potentially at elevated risk of HIV infection (eg, HIV -positive partner, IV drug use by self or by partner)

• additional criteria apply, please contact the investigator for more information